Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ARYx Therapeutics, a biopharmaceutical company focused on developing a portfolio of potentially safer oral drugs, has appointed David Beier to its board of directors.
Subscribe to our email newsletter
Mr Beier is a veteran of the biotechnology industry and has been instrumental in the development of US public policy impacting biotechnology companies, having served in both the industry and the Bill Clinton administration.
Mr Beier is currently senior vice president of global government and corporate affairs for Amgen and is responsible for global healthcare issues, health economics and outcomes research, corporate communications and philanthropy, and government affairs at the US federal and state levels as well as with international governmental entities and organizations.
Prior to joining Amgen, he was a partner in the international law firm of Hogan & Hartson, and was vice president of government affairs and public policy for Genentech. He received a BA from Colgate University and his JD from Albany Law School.
Paul Goddard, ARYx chairman and CEO, said: “I am very pleased to welcome David to our board of directors. As each of our products moves through development, someone with David’s extraordinary experience will be invaluable in helping to position them in the marketplace. His expertise in health economics, reimbursement and outcomes research will aid ARYx enormously.”